<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">258</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2019-18-3-35-40</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunophenotypic characterization of acute megakaryoblastic leukaemia in children</article-title><trans-title-group xml:lang="ru"><trans-title>Иммунофенотипическая характеристика острого мегакариобластного лейкоза у детей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2521-5353</contrib-id><name-alternatives><name xml:lang="en"><surname>Alexenko</surname><given-names>M. Yu.</given-names></name><name xml:lang="ru"><surname>Алексенко</surname><given-names>М. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2685-674X</contrib-id><name-alternatives><name xml:lang="en"><surname>Illarionova</surname><given-names>O. I.</given-names></name><name xml:lang="ru"><surname>Илларионова</surname><given-names>О. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9329-1828</contrib-id><name-alternatives><name xml:lang="en"><surname>Verzhbitskaya</surname><given-names>N/ Yu.</given-names></name><name xml:lang="ru"><surname>Вержбицкая</surname><given-names>Т. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Ekaterinburg</italic></p></bio><bio xml:lang="ru"><p><italic>Екатеринбург</italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9634-5828</contrib-id><name-alternatives><name xml:lang="en"><surname>Zerkalenkova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Зеркаленкова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6689-5861</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikova</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Новикова</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Rostov-on-Don</italic></p></bio><bio xml:lang="ru"><p><italic>Ростов-на-Дону</italic></p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8580-3499</contrib-id><name-alternatives><name xml:lang="en"><surname>Panferova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Панферова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1885-3912</contrib-id><name-alternatives><name xml:lang="en"><surname>Fechina</surname><given-names>L. G.</given-names></name><name xml:lang="ru"><surname>Фечина</surname><given-names>Л. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Ekaterinburg</italic></p></bio><bio xml:lang="ru"><p><italic>Екатеринбург</italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9881-6221</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsaur</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Цаур</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Ekaterinburg</italic></p></bio><bio xml:lang="ru"><p><italic>Екатеринбург</italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2352-7716</contrib-id><name-alternatives><name xml:lang="en"><surname>Olshanskaya</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Ольшанская</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0889-6986</contrib-id><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Alexander M. Popov</bold>, MD, PhD, Head of Hemoblastosis immunophenotyping laboratory of the Department of pediatric oncological surgery</p><p><italic>117997, Moscow, Samory Mashela st., 1 </italic><italic/></p></bio><bio xml:lang="ru"><p><bold>Попов Александр Михайлович</bold>, кандидат медицинских наук, заведующий лабораторией иммунофенотипирования гемобластозов</p><p><italic>117997, Москва, ГСП-7, ул. Саморы Машела, 1</italic></p></bio><email>uralcytometry@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitriy Rogachev National Medical Research Center of Pediatric Hematology&#13;
, Oncology, Immunology Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Regional Children Clinical Hospital № 1</institution></aff><aff><institution xml:lang="ru">ГАУЗ СО «Областная детская клиническая больница»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Research Institute of Medical Cell Technologies</institution></aff><aff><institution xml:lang="ru">ГАУЗ СО «Институт медицинских клеточных технологий»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Rostov Institute of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-09-13" publication-format="electronic"><day>13</day><month>09</month><year>2019</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>35</fpage><lpage>40</lpage><history><date date-type="received" iso-8601-date="2019-09-12"><day>12</day><month>09</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-09-12"><day>12</day><month>09</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/258">https://hemoncim.com/jour/article/view/258</self-uri><abstract xml:lang="en"><p>Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia, in which the bone marrow produce increased numbers of immature abnormal megakaryoblasts. AMKL is rare both in children and adults, but is the most frequent subtype of acute myeloid leukemia (AML) in children with Down syndrome. Morphological diagnosis of this disease could be complicated, thus flow cytometry plays a crucial role in the diagnostics of AMKL. The aim of the present study was to investigate the immunophenotypic characteristics of AMKL in children. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The study group included 103 patients with AMKL. Antigen expression profile was assessed by multicolor flow cytometry. We identified three groups of patients according to different levels of CD45 expression, and in majority of patients (74%) high level of CD45 expression was detected. Significant immunophenotypic differences between these groups were found. In 56% of patients trisomy of 21 chromosome was detected. Among these patients, 86% belonged to group of high CD45 expression. Moreover, children with trisomy 21 represented the majority in the group with high level of CD45 expression (64%). Also, there were found several significant differences between patients with and without trisomy 21 within the group of high CD45 expression. This study demonstrated the wide immunophenotypic heterogeneity of AMKL. In general, the revealed diversity obviously reflects the biological heterogeneity of this AML subtype.</p><p> </p></abstract><trans-abstract xml:lang="ru"><p>Острый мегакариобластный лейкоз (ОМКЛ) – разновидность острого миелоидного лейкоза (ОМЛ), в основе которого лежит избыточная пролиферация мегакариобластов в костном мозге. ОМКЛ – редкий вариант ОМЛ как среди детей, так и среди взрослых, но характеризуется высокой частотой среди пациентов с синдромом Дауна. Морфологическая диагностика ОМКЛ сопряжена с рядом трудностей, поэтому ключевую роль в диагностике играет иммунофенотипирование. Данное исследование поддержано Независимым этическим комитетом и утверждено решением Ученого совета НМИЦ ДГОИ. Цель исследования – комплексная оценка иммунофенотипа опухолевых клеток у детей с ОМКЛ. Исследуемую группу составили 103 образца костного мозга детей с ОМКЛ. Иммунофенотипирование проводили методом проточной цитометрии. По результатам исследования выявлено три группы пациентов с разным уровнем экспрессии CD45, при этом большинство пациентов (74%) имело высокую экспрессию данного маркера. При комплексной оценке фенотипа выявлен ряд других достоверных отличий между этими группами. У 56% больных ОМКЛ была обнаружена трисомия 21 хромосомы в костном мозге, при этом именно дети с трисомией составили большинство в группе пациентов с высокой экспрессией CD45 (64% в группе и 86% всех пациентов с трисомией). Кроме того, выявлен ряд достоверных фенотипических отличий у пациентов с трисомией и без нее в рамках группы с высокой экспрессией CD45. Данное исследование продемонстрировало существенную иммунофенотипическую гетерогенность ОМКЛ. В целом выявленное разнообразие, очевидно, отражает биологическую неоднородность данной группы пациентов с ОМЛ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acute megakaryoblastic leukaemia</kwd><kwd>AMKL</kwd><kwd>AML</kwd><kwd>trisomy 21</kwd><kwd>CD45</kwd><kwd>children</kwd><kwd>flow cytometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>острый мегакариобластный лейкоз</kwd><kwd>ОМКЛ</kwd><kwd>ОМЛ</kwd><kwd>трисомия 21</kwd><kwd>CD45</kwd><kwd>дети</kwd><kwd>иммунофенотипирование</kwd><kwd>проточная цитометрия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Gruber T.A., Downing J.R. The biology of pediatric acute megakaryoblastic leukemia. Blood 2016; 126 (8): 943–9.</mixed-citation><mixed-citation xml:lang="ru">Gruber T.A., Downing J.R. The biology of pediatric acute megakaryoblastic leukemia. Blood 2016; 126 (8): 943–9.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.</mixed-citation><mixed-citation xml:lang="ru">Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Mejía-Aranguré J. M. (ed.). Etiology of Acute Leukemias in Children. Springer International Publishing Switzerland; 2016.</mixed-citation><mixed-citation xml:lang="ru">Mejía-Aranguré J. M. (ed.). Etiology of Acute Leukemias in Children. Springer International Publishing Switzerland; 2016.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Roy A., Roberts I., Norton A., Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol 2009; 147 (1): 3–12.</mixed-citation><mixed-citation xml:lang="ru">Roy A., Roberts I., Norton A., Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol 2009; 147 (1): 3–12.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Илларионова О.И., Горчакова М.В., Русанова Е.Б., Прохорова Ю.А., Салогуб Г.Н., Осипова Е.Ю. и соавт. Конспект клинической цитометрии: острый мегакариобластный лейкоз. Клиническая лабораторная диагностика 2015; 60 (7): 42–9.</mixed-citation><mixed-citation xml:lang="ru">Илларионова О.И., Горчакова М.В., Русанова Е.Б., Прохорова Ю.А., Салогуб Г.Н., Осипова Е.Ю. и соавт. Конспект клинической цитометрии: острый мегакариобластный лейкоз. Клиническая лабораторная диагностика 2015; 60 (7): 42–9.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Karandikar N.J., Aquino D.B., McKenna R.W., Kroft S.H. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001 Aug; 116 (2): 204–10.</mixed-citation><mixed-citation xml:lang="ru">Karandikar N.J., Aquino D.B., McKenna R.W., Kroft S.H. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001 Aug; 116 (2): 204–10.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Bene M., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9 (10): 1783–6.</mixed-citation><mixed-citation xml:lang="ru">Bene M., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9 (10): 1783–6.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 298 (7731): 971–2.</mixed-citation><mixed-citation xml:lang="ru">Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 298 (7731): 971–2.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Новикова И.А., Вержбицкая Т.Ю., Мовчан Л.В., Цаур Г.А., Белевцев М.В., Попов А.М. Стандарт россий-ско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей. Онкогематология 2018; 13 (1): 73–82.</mixed-citation><mixed-citation xml:lang="ru">Новикова И.А., Вержбицкая Т.Ю., Мовчан Л.В., Цаур Г.А., Белевцев М.В., Попов А.М. Стандарт россий-ско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей. Онкогематология 2018; 13 (1): 73–82.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Boztug H., Schumich A., Pötschger U., Mühlegger N., Kolenova A., Reinhardt K., et al. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. Cytometry Part B (Clinical Cytometry) 2013; 84B: 370–8. </mixed-citation><mixed-citation xml:lang="ru">Boztug H., Schumich A., Pötschger U., Mühlegger N., Kolenova A., Reinhardt K., et al. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. Cytometry Part B (Clinical Cytometry) 2013; 84B: 370–8.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
